PMID- 23506556
OWN - NLM
STAT- MEDLINE
DCOM- 20140127
LR  - 20220330
IS  - 1744-8328 (Electronic)
IS  - 1473-7140 (Linking)
VI  - 13
IP  - 6
DP  - 2013 Jun
TI  - Diarrhea associated with afatinib: an oral ErbB family blocker.
PG  - 729-36
LID - 10.1586/era.13.31 [doi]
AB  - Gastrointestinal (GI) adverse events (AEs) are frequently observed in patients 
      receiving EGF receptor (EGFR; also known as HER1 or ErbB1) tyrosine kinase 
      inhibitor therapy. GI AEs are among the most common and most impactful on a 
      patient's quality of life. Severe diarrhea can result in fluid and electrolyte 
      losses, leading to dehydration, electrolyte imbalances and renal insufficiency. 
      Afatinib is an irreversible, oral, ErbB family blocker, inhibiting EGFR (ErbB1), 
      HER2 (ErbB2) and ErbB4 receptor kinases. It also inhibits transphosphorylation of 
      ErbB3. Similar to reversible tyrosine kinase inhibitors of EGFR, GI AEs - in 
      particular, diarrhea - have frequently been observed in afatinib-treated 
      patients. This article summarizes current data on afatinib-associated diarrhea 
      and provides strategies for its management. Patient education, early 
      identification, timely management and ongoing assessment will help to prevent 
      aggravation, afatinib dose reductions or therapy discontinuation, encouraging 
      patient compliance and allowing patients to obtain the maximum therapeutic 
      benefit from this agent.
FAU - Yang, James Chih-Hsin
AU  - Yang JC
AD  - Graduate Institute of Oncology and Cancer Research Center, National Taiwan 
      University Hospital, Taipei, Taiwan. chihyang@ntu.edu.tw
FAU - Reguart, Noemi
AU  - Reguart N
FAU - Barinoff, Jana
AU  - Barinoff J
FAU - Kohler, Jens
AU  - Kohler J
FAU - Uttenreuther-Fischer, Martina
AU  - Uttenreuther-Fischer M
FAU - Stammberger, Uz
AU  - Stammberger U
FAU - O'Brien, Dennis
AU  - O'Brien D
FAU - Wolf, Jurgen
AU  - Wolf J
FAU - Cohen, Ezra E W
AU  - Cohen EE
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20130318
PL  - England
TA  - Expert Rev Anticancer Ther
JT  - Expert review of anticancer therapy
JID - 101123358
RN  - 0 (Protein Kinase Inhibitors)
RN  - 0 (Quinazolines)
RN  - 41UD74L59M (Afatinib)
RN  - EC 2.7.10.1 (ERBB2 protein, human)
RN  - EC 2.7.10.1 (ERBB4 protein, human)
RN  - EC 2.7.10.1 (ErbB Receptors)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
RN  - EC 2.7.10.1 (Receptor, ErbB-4)
SB  - IM
MH  - Administration, Oral
MH  - Afatinib
MH  - Diarrhea/*chemically induced/diet therapy
MH  - ErbB Receptors/antagonists & inhibitors
MH  - Humans
MH  - Protein Kinase Inhibitors/*adverse effects
MH  - Quinazolines/administration & dosage/*adverse effects
MH  - Receptor, ErbB-2/antagonists & inhibitors
MH  - Receptor, ErbB-4
EDAT- 2013/03/20 06:00
MHDA- 2014/01/28 06:00
CRDT- 2013/03/20 06:00
PHST- 2013/03/20 06:00 [entrez]
PHST- 2013/03/20 06:00 [pubmed]
PHST- 2014/01/28 06:00 [medline]
AID - 10.1586/era.13.31 [doi]
PST - ppublish
SO  - Expert Rev Anticancer Ther. 2013 Jun;13(6):729-36. doi: 10.1586/era.13.31. Epub 
      2013 Mar 18.